'Incorrect' To Assume Interchangeables Are Safer, More Effective Than Biosimilars, Says FDA
Executive Summary
US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.
You may also be interested in...
Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”
Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”
Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top Five India League
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.